Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into patient DNA — could raise new questions for the gene therapy field.
Source: BioPharma Dive
Read more →In first clinical result using “chemogenetic” strategy, a team in China treated three patients to control epilepsy
Source: Science
Read more →New cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.
Source: STAT
Read more →Novartis acknowledged seven instances of tumors being found in children who were treated with Zolgensma for spinal muscular atrophy
Source: STAT
Read more →Skin is remarkably good at keeping things out of the body. Typically, that's a positive. It becomes an issue when medicine needs to get in. Swallow a pill to treat a skin condition, and the medicine enters your stomach, moves into your bloodstream and travels throughout your body—all to reach a problem in your skin.
Source: Phys.org
Read more →A breathable patch made from Korean mulberry paper combines 3D printed microneedles with wireless uric acid sensing, offering a potential platform for future wearable health monitoring.
Source: Nanowerk
Read more →Genome editing is not designed to replace neurons or retinal cells that have already been lost. In this article, experts from four companies—eGenesis, Epicrispr, KOMO Biosciences, and Sumitomo Pharma America—discuss how they are moving beyond conventional CRISPR to develop novel approaches for treating disease.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Harnessing viral mimicry mechanisms enhances cancer vaccination by improving long-range antigen presentation and T cell activation.
Source: Nature Nanotechnology
Read more →The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its funding model combines initial seed investment with commercial revenue and non-traditional funding sources.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Nine patients who have received Novartis' spinal muscular atrophy gene therapy Zolgensma have developed tumors following their treatment, the company confirmed Thursday. Seven of those cases were disclosed for the first time. Two may be ...
Source: Endpoints News
Read more →Three years ago, a trial for a sickle cell gene-editing therapy a decade in the making ended abruptly after the first patient suffered a serious adverse event. Now, the therapy…
Source: STAT
Read more →Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.
Source: STAT
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
